Categories Uncategorized

Want to Learn More About the Psychedelic Experience? Read These Books!

With the many studies being conducted on the potential benefits that psychedelic substances may offer to humans as well as the up and coming psychedelic companies, psychedelics are going mainstream, and you must be having lots of questions about these substances.

To educate yourself more on the spiritual and therapeutic potential of psychedelics, below are a few must-read psychedelic works that cover a range of related subjects with details on various clinical studies that have been done over the years.

  1. Drugged by Richard J Miller

Richard J Miller, a Northwestern pharmacology professor, was first introduced to psychedelics while attending Woodstock, a music festival that was held from August 15th to 18th, in 1969. He says that this “religious experience” is what inspired his pharmacology career. He wanted to find out how these substances altered the body’s neurochemistry so intensely.

The book takes you through Miller’s journey as he studies a range of mind-altering substances including cannabis, opium, coffee and antidepressants. The chapters that are dedicated to psychedelics offer great insights on their spiritual and clinical applications.

  1. Am I Dreaming? by James Kingsland

In his book, titled Am I dreaming? James Kingsland, a science journalist, takes a look at a broader view of various altered states of consciousness, including virtual reality, lucid dreaming, hypnotic trances as well as micro dosing with psychedelics.

He recounts his intense personal experiences with LSD, ayahuasca and psilocybin in the book. His journey is valuable to anyone interested in the science behind these psychedelic substances.

  1. Hallucinogens by Charles Grob

Charles Grob, a professor of Psychiatry and Biobehavioral Sciences from the UCLA Medical Center, was the first researcher that received approval to study ayahuasca and MDMA clinically in the 90s. His pioneering work in these spheres has significantly catapulted the psychedelic research field forward.

The 2002 release features writings of various thinkers, such as Terence McKenna, Ralph Metzner, Rick Strassman and Huston Smith as well as a Dr. Andrew Weil interview. The book ends with remarkable essays by Grob on the politics of MDMA research, the psychology of ayahuasca as well as the psychiatric research on hallucinogens.

  1. Psychedelic Medicine by Dr. Richard Louis Miller

Dr. Richard Louis Miller has been a clinical psychologist for more than 50 years. This book is a collection of interviews from his popular radio talk show, featuring Amanda Feilding, David Nichols, Roland Griffiths, Stanislav Grof, Dennis McKenna and Roland Griffiths. They cover various issues such as the use of MDMA as a treatment for PTSD and psilocybin for depression treatment. In addition to this, there are important conversations included from Rick Doblin, who is the Multidisciplinary Association for Psychedelic Studies (“MAPS”) founder.

However, these are not the only books that discuss psychedelics. There are numerous volumes from different authors available, so if you would like to educate yourself, you just have to look. Or better yet, get in touch with companies like Pure Extract Technologies Inc. and they could hook you up with some great resources!

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

4 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…

4 weeks ago

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…

4 weeks ago